Systemic lupus erythematosus is a complex autoimmune disease in which the immune system turns against the body’s own tissues, attacking the skin, joints, kidneys, blood cells, and other organs with chronic inflammation. Genetics plays a substantial role in determining who develops lupus, and many of the genetic regions associated with disease risk have been catalogued for years through large-scale association studies. A major challenge, however, has been moving from statistical association to biological mechanism. Knowing that a stretch of DNA correlates with disease risk says little about what the inherited variant actually does inside immune cells, or why it increases susceptibility not just to lupus but frequently to several autoimmune conditions at once. The new study addresses that gap directly by dissecting what one of the most prevalent lupus-risk haplotypes does to the function of IRF7, a gene whose protein product orchestrates the production of type I interferons, the chemical alarm signals that mobilize antiviral defense throughout the body.

IRF7 helps cells respond to viral infection by activating the production of type I interferons, most notably interferon-alpha, or IFN-α. These signaling molecules are essential components of innate immunity, spreading rapidly from infected cells to their neighbors and instructing them to enter a defensive state that makes viral replication far more difficult. But type I interferon signaling has long been strongly implicated in lupus as well. Many patients with lupus carry a chronically elevated interferon activity in their blood, a phenomenon so consistent that researchers refer to it as the ‘interferon signature,’ and therapies designed to block this pathway have already been approved for treating the disease. The Cincinnati Children’s team reasoned that the connection between these two observations, effective antiviral defense on one side and pathological interferon activity on the other, might run through the genetic variation within IRF7 itself.

That reasoning proved correct. The researchers found that the lupus risk haplotype increases IRF7-dependent induction of IFN-α. In practical terms, individuals carrying this common genetic configuration mount a stronger interferon response under the conditions studied, meaning their antiviral alarm system can ring louder and faster when a viral threat is detected. That heightened responsiveness can be a genuine asset in fighting infection. Yet the very same biology can also promote excessive or inappropriate immune activation, tipping the balance of the immune system toward the self-directed inflammation that defines lupus. The study thereby exposes what the authors describe as an important biological tradeoff, in which a single inherited configuration of the immune system confers both an advantage and a vulnerability depending on context.

The evolutionary implications are striking. A more vigorous antiviral immune response may have been enormously beneficial throughout human history, particularly during eras when infectious diseases represented one of the greatest threats to survival. Populations in which individuals responded more forcefully to viral invasion may have withstood epidemics that devastated others. But an immune system that is especially sensitive to viral signals also carries a greater inherent tendency to cross the line from protective immunity into autoimmunity. The new findings therefore suggest that at least some lupus risk variants should not be thought of as ‘defective’ versions of immune genes at all. Instead, they represent versions of the immune system that simply perform differently, offering an advantage in one environment while increasing disease susceptibility in another. This reframing helps explain why such variants remained common: natural selection may have favored them precisely because of the very biology that now contributes to autoimmune disease.

Sam Virolainen, PhD, first author of the study and a graduate of the Immunology Graduate Program at Cincinnati Children’s, said the findings help explain why a genetic variant linked to lupus remained so common and how, biologically, it affects the immune system more broadly. Reflecting on the training that shaped the work, Virolainen noted an appreciation gained during doctoral research in the Kottyan and Weirauch laboratories that many genetic risk factors can contribute to multiple diseases, especially when the immune system is involved. That multiscale perspective, spanning molecular regulation, cellular signaling, and population genetics, is evident throughout the study’s design and interpretation, and it underscores how a variant’s effect can ripple across very different levels of biological organization.

The work also feeds into a larger and still-unresolved question: how inherited genetic risk interacts with viral infection in the development of autoimmunity. For years, researchers have recognized a strong relationship between Epstein-Barr virus, or EBV, and lupus. Nearly everyone is exposed to EBV at some point in their lives, yet only a small fraction of those exposed ever develop lupus. Genetics may help explain why the consequences of the same viral exposure differ so dramatically from one person to the next. The research team’s previous work examined how viral proteins, including those produced by EBV, interact with the human genome at regions associated with autoimmune disease. The new IRF7 study approaches the gene-virus relationship from the opposite direction. Rather than asking how a virus interacts with genetically susceptible cells, the team asked how inherited genetic variation changes the antiviral response itself, and the answer places both processes on converging molecular roads.

‘Together, these studies support a model in which genetic susceptibility and viral exposure are not independent risk factors. They can converge on the same regulatory pathways,’ said Kottyan. In this model, a person’s inherited genome shapes how strongly their immune system reacts to infection, while viral infection in turn activates molecular pathways that are already tuned by that genetic makeup. In some individuals, the interaction of the two may explain how an ordinary antiviral immune response develops into chronic autoimmune inflammation. The lupus-risk IRF7 haplotype amplifies the interferon arm of this convergence, but the principle likely extends to other immune genes and other autoimmune conditions, offering a framework in which genetics and environment are treated as intertwined rather than separate contributors to disease.

The study does not immediately change how lupus is diagnosed or treated, and carrying this genetic haplotype does not mean that someone will develop the disease. Lupus arises from the combined effects of many genetic variants together with environmental exposures and other biological factors, and no single inherited element is decisive on its own. However, the research demonstrates how scientists can move beyond simply identifying genetic risk factors to understanding, at a mechanistic level, how those variants alter immune function. Studies of this kind help build a foundation for future research into what drives disease and why its course differs from person to person. ‘I am hopeful that our work will increase our understanding of not just lupus biology but other diseases with similar genetic and immunologic complexities,’ said Virolainen. Many disease-associated variants have already been identified, but their biological effects remain unclear. By clarifying the molecular pathways involved, the Cincinnati Children’s team and their collaborators, who spanned institutions across 13 U.S. states and territories and six countries, may ultimately help guide therapies that target disease more precisely while preserving the normal antiviral function that those same variants evolved to protect.

Subject of Research: Genetic and immunological mechanisms linking a common IRF7 haplotype to enhanced antiviral defense and increased lupus risk

Article Title: When Antiviral Defense and Autoimmunity Collide: New Insights into Lupus Genetics

Article References: When Antiviral Defense and Autoimmunity Collide: New Insights into Lupus Genetics. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: lupus, systemic lupus erythematosus, IRF7, interferon-alpha, autoimmunity, antiviral immunity, genetic haplotype, Epstein-Barr virus, transcription factor, immune genetics, Cincinnati Children's, interferon signature

Cell engineering has become one of the most promising frontiers in biomedicine, underpinning therapies ranging from CAR-T cancer treatments to engineered probiotics. Yet the dominant tool for endowing cells with new abilities—genetic manipulation—carries inherent constraints. Editing multiple genes simultaneously is technically complex, and the tools that work in one species often fail to translate to another. As a result, building cells with sophisticated, multi-part functionalities through genetic means remains slow, costly and sometimes infeasible.

The cell surface offers a compelling alternative target. Because it mediates virtually every interaction a cell has with its environment, the surface is where therapeutic behavior can be most directly tuned. Surface biomolecules present a rich array of functional groups—amines, thiols and other reactive chemistry—that serve as natural anchoring points for chemical modification. Wang and Liu exploited this chemical accessibility by harnessing dopamine, a small molecule that self-polymerizes under mild, alkaline conditions into polydopamine, a adhesive layer first described in a landmark 2007 Science paper on mussel-inspired surface chemistry.

The beauty of the method lies in its simplicity and universality. When dopamine is added to a suspension of living bacteria under the right conditions, it polymerizes directly on the cell surface, forming a thin reactive coating that can simultaneously capture a second component of choice. In the protocol’s first procedure, that component is polyethylene glycol, or PEG, a hydrophilic polymer long known to help nanoparticles slip through mucus. The result is a PEGylated bacterium capable of penetrating the intestinal mucus layer and reinforcing the mucosal barrier—a potential preventive strategy against colitis. Excluding bacterial culture, preparing these mucus-penetrating bacteria takes roughly three hours.

The second procedure goes a step further with dual-functionalization. Here, polydopamine serves as the bridge between two distinct bioactive molecules on a single bacterium: an anti-PD1 antibody, a celebrated immune checkpoint inhibitor, and the S1 subunit of the SARS-CoV-2 spike protein, a viral antigen. The resulting synergy-immunoactivation bacteria are designed to simultaneously provoke anticancer immunity and antiviral immunity, offering a two-in-one platform for treating tumors while guarding against infection. This dual-functionalization procedure requires only about one hour of hands-on preparation time beyond bacterial culture.

Compared with conventional genetic manipulation and existing physicochemical surface modification techniques, the protocol’s versatility stands out. The polydopamine intermediate accepts both natural biological macromolecules, such as proteins and antibodies, and synthetic materials, and it tolerates the attachment of multiple diverse components in sequence. Because the chemistry does not depend on species-specific genetic machinery, it can in principle be applied to a wide range of cell types, from probiotic Escherichia coli Nissle 1917 to potentially other living cells, making it a genuinely cross-species platform.

The scientific foundations of the work draw on more than a decade of polydopamine research. Catecholic chemistry, first systematized for surface modification by Messersmith, Lee and colleagues, has been applied to countless materials, but extending it to living cells required careful optimization to ensure the polymerization conditions do not compromise cell viability. The Wang and Liu groups had previously demonstrated polymerization-mediated multifunctionalization of living cells in Advanced Materials in 2021, and their primary research papers—published in Nature Biomedical Engineering in 2024 on mucus-penetrating PEGylated bacteria and in Advanced Materials in 2023 on hybrid immunoactive nanosurface bacteria—provide the proof-of-concept data that underpin this protocol.

The therapeutic implications are substantial. For inflammatory bowel disease, the mucus-penetrating bacteria represent a novel way to shore up a failing intestinal barrier rather than simply delivering drugs. For oncology, bacteria coated with checkpoint inhibitors concentrate immunotherapy at tumor sites, potentially reducing the systemic toxicity associated with injected antibodies while leveraging the natural tumor-homing behavior of certain bacterial strains. And because the coating chemistry is modular, the same scaffold could in principle carry different antigen–antibody pairs to address other cancers or emerging viral threats.

The authors also confront the practical challenges facing any live biotherapeutic. Regulatory frameworks for live biotherapeutic products, as outlined by the US Food and Drug Administration, demand rigorous characterization of manufacturing and control, and a surface-engineered bacterium must demonstrate stability, safety and reproducibility at every step. The protocol addresses these concerns by providing detailed characterization procedures, including assessments of coating thickness, surface composition, bacterial viability, mucus penetration, and the immunogenicity and intratumoral distribution of the dual-functionalized bacteria. Jinyao Liu has additionally filed a patent related to the technology, signaling commercial interest alongside the academic contribution.

By transforming cell surface engineering from a specialized genetic exercise into an accessible chemical operation, the protocol lowers the barrier to entry for laboratories seeking to develop next-generation living therapeutics. The authors anticipate that the platform will offer valuable guidance for engineering living cells with designable, tailorable functionalities for innovative cell-based therapy. If the approach translates from the bench to the clinic as hoped, the humble chemistry of mussel glue may soon help dress living cells for battle against some of medicine’s most stubborn diseases.

Subject of Research: Dopamine polymerization-mediated chemical surface functionalization of living cells for cell-based therapy

Article Title: Dopamine polymerization-mediated surface functionalization of living cells for advanced therapeutic applications

Article References: Dopamine polymerization-mediated surface functionalization of living cells for advanced therapeutic applications. (n.d.). https://doi.org/10.1038/s41596-026-01422-1

Image Credits: AI Generated

DOI: 10.1038/s41596-026-01422-1

Keywords: dopamine polymerization, polydopamine, surface functionalization, living cells, bacterial therapeutics, mucus-penetrating bacteria, PEGylation, immune checkpoint inhibitor, anticancer immunity, antiviral immunity, cell engineering, colitis

Long noncoding RNAs, typically defined as transcripts longer than two hundred nucleotides that are not translated into proteins, were once dismissed by many researchers as transcriptional noise. Early genome sequencing projects revealed that while only a small fraction of the human genome encodes proteins, the vast majority of it is transcribed into RNA. Skeptics argued that most of these transcripts were accidental byproducts of a cellular machinery that transcribes promiscuously. Over the past two decades, however, careful functional studies have dismantled that view. Individual long noncoding RNAs have been shown to sculpt chromatin, modulate the stability and translation of messenger RNAs, serve as scaffolds for multi-protein complexes, and act as molecular decoys that sequester transcription factors or microRNAs. Their regulatory reach extends across nearly every layer of gene expression, and their expression patterns are often exquisitely specific to particular cell types, developmental stages, and physiological conditions, including infection.

What makes the cross-kingdom framing particularly compelling is that long noncoding RNAs are not a peculiarity of animals. Plants produce them in abundance, and plant pathologists have documented RNA molecules that move from fungal pathogens into plant cells and vice versa. Small RNAs were the first cross-kingdom RNA travelers to be described in detail, with fungal pathogens such as Botrytis cinerea shown to deliver small RNAs into plant cells where they hijack the host’s own RNA interference machinery to suppress immune genes. Long noncoding RNAs now appear to participate in comparable exchanges, functioning both as sources of regulatory small RNAs and as independent effectors in their own right. In agricultural contexts, this discovery has opened an entirely new frontier: if pathogen RNAs silence crop immune genes, then engineered host RNAs might be deployed to silence essential pathogen genes, a strategy sometimes described as host-induced gene silencing.

In mammalian systems, the interplay between long noncoding RNAs and pathogens is equally rich. Upon infection, host cells reprogram their long noncoding RNA landscape on a massive scale. Interferon signaling, the centerpiece of antiviral immunity, induces a constellation of noncoding transcripts whose functions are only beginning to be mapped. Some of these RNAs amplify antiviral responses, acting as positive regulators that stabilize interferon-stimulated messenger RNAs or promote the signaling cascades triggered by pattern-recognition receptors. Others do the opposite, serving as brakes on inflammation that prevent immune damage to host tissues. Pathogens, in turn, have learned to manipulate this layer of regulation. Viruses encode their own noncoding RNAs and also reshape the abundance of host long noncoding RNAs, co-opting regulatory molecules to create a cellular environment favorable to viral replication, persistence, and escape from immune surveillance.

Bacterial pathogens add yet another dimension to the dialogue. Although bacteria do not possess the same RNA processing machinery as eukaryotes, they are masters of RNA regulation, using small RNAs and structured RNA elements to fine-tune gene expression in response to environmental cues. Emerging work suggests that bacterial RNAs can be released into host cells, whether through outer membrane vesicles, secretion systems, or the controlled lysis of bacterial cells, and that these molecules can modulate host signaling pathways. Conversely, host long noncoding RNAs influence the outcome of bacterial infection by regulating the expression of genes involved in innate immunity, inflammasome activation, autophagy, and cell death. Each of these pathways is a battleground, and RNA regulation sits at the heart of the fight.

The mechanistic versatility of long noncoding RNAs helps explain why they are such effective mediators of this dialogue. Unlike proteins, which must be synthesized, folded, and often trafficked through elaborate pathways, RNAs can be produced rapidly and can act through base-pairing interactions that are comparatively simple to predict and, at least in principle, to engineer. A single long noncoding RNA can interact with DNA, other RNAs, and proteins simultaneously, functioning as a hub that integrates multiple regulatory inputs. This multifunctionality means that a pathogen that targets one host long noncoding RNA can, in a single move, perturb an entire regulatory network. It also means that experimental perturbation of these RNAs, through antisense oligonucleotides, small interfering RNAs, or CRISPR-based approaches, can reveal network-level effects that single-gene knockout studies of proteins might miss.

Technological advances have driven much of the recent progress. Long-read sequencing technologies now allow full-length characterization of transcript isoforms, revealing complexity that short-read approaches obscured. Strand-specific and single-cell RNA sequencing methods have made it possible to profile the noncoding transcriptome of individual infected cells, exposing the heterogeneity of host responses within a tissue. Cross-kingdom RNA detection has benefited from computational pipelines designed to distinguish pathogen-derived reads from host transcripts, a nontrivial challenge given the low abundance of microbial RNAs within a sea of host RNA. Functional validation remains the rate-limiting step: assigning a concrete mechanism to a differentially expressed long noncoding RNA requires loss-of-function and gain-of-function experiments, mapping of interaction partners, and careful demonstration that observed effects are not artifacts of off-target perturbation. The field has matured considerably in its rigor, and the commentary in Cell Research reflects that maturation, emphasizing that the most convincing examples of cross-kingdom RNA communication are those in which the transferred RNA is detected in the recipient, its target is identified, and a functional consequence is demonstrated.

The translational implications are substantial. Host long noncoding RNAs that promote antiviral or antibacterial defense could serve as biomarkers that distinguish active infection from convalescence, or as predictors of disease severity. Therapeutically, RNA-based drugs have finally come of age: antisense oligonucleotides and small interfering RNA therapeutics have been approved for a range of conditions, and the mRNA vaccine success of the COVID-19 pandemic demonstrated that RNA delivery technologies can be scaled to global public health needs. Applying these tools to infection biology, whether by enhancing protective host noncoding RNAs or by directly silencing pathogen transcripts, is a logical next step. In agriculture, RNA-based crop protection strategies are already moving from the laboratory to the field, and a deeper understanding of cross-kingdom RNA exchange will inform both the design of such products and the assessment of their ecological effects on the wider microbiome.

Significant questions remain open. The mechanisms by which RNAs cross cellular boundaries, survive extracellular environments, and enter recipient cells are still incompletely understood, and the physiological relevance of some reported transfers continues to be debated. Dosage is a critical issue: RNA communication depends on molecules reaching functional concentrations in recipient cells, and measuring that accurately in vivo is technically demanding. Specificity is another challenge, since long noncoding RNAs often act at low levels through partial complementarity, raising the risk of unintended interactions when RNAs are manipulated therapeutically. Nonetheless, the conceptual shift is clear and consequential. Host and pathogen are no longer best understood as two organisms exchanging only molecular blows at the protein level; they are two transcriptomes in conversation, each reading and misreading the other’s RNA messages. The commentary’s central message, that long noncoding RNAs broaden the host–pathogen dialogue across kingdoms, captures a field in the midst of redefining itself, and it points toward a future in which the language of RNA becomes as central to infection biology as the language of proteins has always been.

Subject of Research: The role of long noncoding RNAs in cross-kingdom host–pathogen communication and infection biology.

Article Title: Long noncoding RNAs cross kingdoms to broaden host–pathogen dialogue

Article References: Halilovic, L., & Jin, H. (2026). Long noncoding RNAs cross kingdoms to broaden host–pathogen dialogue. Cell Research. https://doi.org/10.1038/s41422-026-01289-7

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01289-7

Keywords: long noncoding RNAs, host-pathogen interactions, cross-kingdom RNA, infection biology, antiviral immunity, gene regulation, RNA therapeutics, plant pathology, viral replication, interferon signaling, host-induced gene silencing, Cell Research